LSTA logo

LSTA
Lisata Therapeutics Inc

8,927
Mkt Cap
$40.89M
Volume
77,681.00
52W High
$4.89
52W Low
$1.81
PE Ratio
-2.18
LSTA Fundamentals
Price
$4.63
Prev Close
$4.64
Open
$4.63
50D MA
$2.39
Beta
0.74
Avg. Volume
28,209.00
EPS (Annual)
-$2.40
P/B
2.33
Rev/Employee
$38,461.54
Loading...
Loading...
News
all
press releases
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their...
PR Newswire·4d ago
News Placeholder
More News
News Placeholder
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA...
PR Newswire·4d ago
News Placeholder
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lisata Therapeutics, Inc. (NASDAQ: LSTA) to Kuva Labs, Inc. for $4.00 per share in cash plus two non-tradeable...
Business Wire·11d ago
News Placeholder
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details
Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.
Stocktwits·11d ago
News Placeholder
All-Cash Buyout Sparks Breakout Move in Biotech Name
Mergers and acquisitions continue to reshape the biotech landscape as larger and better-capitalized players look to secure promising clinical assets earlier in the development cycle. For small and microcap biotech companies, these deals often arrive suddenly, with premium valuations reflecting not just current data but the long-term strategic value of novel platforms and differentiated pipelines. When that happens, the market tends to respond quickly.Shares of Lisata Therapeutics, Inc. (NASDAQ: LSTA) are surging Wednesday after the company announced it has entered into a binding term sheet ...
AllPennyStocks.com·11d ago
News Placeholder
All-Cash Buyout Sparks Breakout Move in Biotech Name
Mergers and acquisitions continue to reshape the biotech landscape as larger and better-capitalized players look to secure promising clinical assets earlier in the development cycle. For small and microcap biotech companies, these deals often arrive suddenly, with premium valuations reflecting not just current data but the long-term strategic value of novel platforms and differentiated pipelines. When that happens, the market tends to respond quickly.Shares of Lisata Therapeutics, Inc. (NASDAQ: LSTA) are surging Wednesday after the company announced it has entered into a binding term sheet ...
AllPennyStocks.com·11d ago
News Placeholder
Why Is Lisata Therapeutics Stock Gaining Today?
Lisata Therapeutics shares surged premarket after Kuva Labs agreed to acquire the company for $4 per share in cash plus two milestone-based CVRs.read more...
Benzinga·11d ago
News Placeholder
Lisata Therapeutics Agrees To Be Acquired By Kuva Labs In $4/shr Cash Deal
(RTTNews) - Lisata Therapeutics, Inc. (LSTA), a clinical-stage pharmaceutical company, on Wednesday said the company has entered into a binding term sheet to be acquired by privately held Kuva Labs...
Nasdaq News: Markets·11d ago
<
...
1
>

Latest LSTA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.